Latest Blood disorders Stories

Team In Training (TNT) in the San Francisco Bay Area is hosting a “Show Us Your Grit” photo contest on Facebook, Twitter and Pinterest. The team that posts the most photos will win a pancake breakfast, 20% off coupon for all teammates to Lombardi Sports and be the face of local TNT marketing efforts for the upcoming season. San Francisco, CA (PRWEB) March 23, 2012 The Leukemia & Lymphoma Society’s Team In Training (TNT), the Bay Area’s largest endurance sports training and...

Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy. “We’re usually very good at clearing these leukemia cells from the blood,” says Geoffrey L. Uy, MD, assistant professor of...

Infants with Batten disease, a rare but fatal neurological disorder, appear healthy at birth. But within a few short years, the illness takes a heavy toll, leaving children blind, speechless and paralyzed. Most die by age 5. There are no effective treatments for the disease, which can also strike older children. And several therapeutic approaches, evaluated in mouse models and in young children, have produced disappointing results. But now, working in mice with the infantile form of...

University Hospitals Case Medical Center cancer researcher helps advance 'individualized' patient care with the find New research published in the March 15 issue of the New England Journal of Medicine (embargoed 5 pm ET March 14) identifies gene mutations associated with improved overall survival with higher doses of chemotherapy for patients with acute myeloid leukemia (AML). According to one of the authors, Hillard M. Lazarus, MD, Director of Novel Cell Therapy at Seidman Cancer...

SAN DIEGO, March 15, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Brian M. Culley, its Chief Executive Officer, has been selected as a 2012 Health Hero by Combined Health Agencies of San Diego County. His nomination was submitted by the San Diego Chapter of the Sickle Cell Disease Association of America. The 18th Annual Health Hero Awards, organized by Combined Health Agencies, honors local companies and individuals for their...

DUBLIN, March 15, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets. - A strategic step...

In trying to unlock the potential of retinoids to treat patients with acute myeloid leukemia (AML), scientists have found the antidepressant called tranylcypromine (TCP) may be the key. Many types of AML can be treated with the retinoid all-trans retinoic acid (ATRA), a vitamin A-derivative. However, ATRA has not been shown to be effective with the more common types of AML. Arthur Zelent, PhD and his team at the Institute of Cancer Research (ICR) have been studying TCP to unlock the...

UNION CITY, Calif., March 13, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer, will present at the Sidoti & Company Sixteenth Annual Institutional Investor Forum on Tuesday, March 20, 2012 at 1:20 p.m. ET. The conference will be held at the Grand Hyatt New York in New York City. About Abaxis Abaxis develops, manufactures,...

A study by the Children's Oncology Group (COG) reported that five-year survival for acute lymphoblastic leukemia (ALL, the most common type of pediatric cancer) among children treated through COG clinical trials increased from 83.7 percent during the period 1990-1994 to 90.4 percent in the period 2000-2005. The improvements in survival were observed among all children over age 1 regardless of age, sex, ethnicity, or subtype of ALL. This analysis, which is the largest study to date of ALL...

21,626-person study shows 90.4 percent survival A 21,626-person study published today in the Journal of Clinical Oncology found that the five-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL), the most common childhood cancer, improved from 83.7 percent in those diagnosed during the years 1990-1994, to 90.4 percent for those diagnosed in the years 2000-2005. "The improved survival is due to using existing drugs better, not because of the...